Toward the Discovery of Vaccine Adjuvants: Coupling In Silico Screening and In Vitro Analysis of Antagonist Binding to Human and Mouse CCR4 Receptors

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Davies, Matthew N ^a,e   Bayry, Jagadeesh ^a,b   Tchilian, Elma Z ^a   Vani, Janakiraman ^b   Shaila, Melkote S ^c   Forbes, Emily K ^a   Draper, Simon J ^a   Beverley, Peter C L ^a   Tough, David F ^a,d   Flower, Darren R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INDIAN INSTITUTE OF SCIENCE   (India)

^d GLAXOSMITHKLINE   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHEMOKINE RECEPTOR CCR4; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2 RECEPTOR ALPHA; VACCINE;

ANIMAL; ARTICLE; BIOLOGY; BIOSYNTHESIS; CATTLE; CD4+ T LYMPHOCYTE; CELL MOTION; CHEMISTRY; CYTOLOGY; DOWN REGULATION; DRUG ANTAGONISM; HUMAN; IN VITRO STUDY; METABOLISM; METHODOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM YOELII; PROTEIN BINDING; REGULATORY T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CATTLE; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM YOELII; PROTEIN BINDING; RECEPTORS, CCR4; T-LYMPHOCYTES, REGULATORY; VACCINES;

EID: 77951239027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008084     Document Type: Article

References (60)

1. Medzhitov R, Janeway CA Jr, (1997) Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9: 4-9.
2. Christopoulos A, Kenakin TG, (2002) protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
3. Bissantz C, (2003) Conformational changes of G protein-coupled receptors during their activation by agonist binding. J Recept Signal Transduct Res 23: 123-153.
4. Luster AD, (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445.
5. Locati M, Murphy PM, (1999) Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med 50: 425-440.
6. Chvatchko Y, Hoogewerf AJ, Meyer A, Alouani S, Juillard P, et al.(2000) A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 191: 1755-1764.
7. Lieberam I, Forster I, (1999) The murine beta-chemokine TARC is expressed by subsets of dendritic cells and attracts primed CD4+ T cells. Eur J Immunol 29: 2684-2694.
8. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, et al.(1999) Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 11: 81-88.
9. Tang HL, Cyster JG, (1999) Chemokine Up-regulation and activated T cell attraction by maturing dendritic cells. Science 284: 819-822.
10. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, et al.(2006) Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 7: 83-92.
11. Bayry J, Triebel F, Kaveri SV, Tough DF, (2007) Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 178: 4184-4193.
12. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S, (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 105: 10113-10118.
13. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, et al.(2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
14. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, et al.(2001) Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194: 847-853.
15. Katou F, Ohtani H, Nakayama T, Ono K, Matsushima K, et al.(2001) Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am J Pathol 158: 1263-1270.
16. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G, et al.(2001) Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 31: 812-822.
17. Liu SQ, Liu SX, Fu YX, (2007) Dynamic domains and geometrical properties of HIV-1 gp120 during conformational changes induced by CD4 binding. J Mol Model 13: 411-424.
18. Allen S, Newhouse B, Anderson AS, Fauber B, Allen A, et al.(2004) Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists. Bioorg Med Chem Lett 14: 1619-1624.
19. Newhouse B, Allen S, Fauber B, Anderson AS, Eary CT, et al.(2004) Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists. Bioorg Med Chem Lett 14: 5537-5542.
20. Bissantz C, Bernard P, Hibert M, Rognan D, (2003) Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins 50: 5-25.
21. Bissantz C, Schalon C, Guba W, Stahl M, (2005) Focused library design in GPCR projects on the example of 5-HT(2c) agonists: comparison of structure-based virtual screening with ligand-based search methods. Proteins 61: 938-952.
22. Chen JZ, Wang J, Xie XQ, (2007) GPCR structure-based virtual screening approach for CB2 antagonist search. J Chem Inf Model 47: 1626-1637.
23. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al.(2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289: 739-745.
24. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al.(2007) Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
25. Engel S, Skoumbourdis AP, Childress J, Neumann S, Deschamps JR, et al.(2008) A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. J Am Chem Soc 130: 5115-5123.
26. Costanzi S, (2008) On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J Med Chem 51: 2907-2914.
27. Bissantz C, Logean A, Rognan D, (2004) High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening. J Chem Inf Comput Sci 44: 1162-1176.
28. Pandit SA, Bostick D, Berkowitz ML, (2003) Molecular dynamics simulation of a dipalmitoylphosphatidylcholine bilayer with NaCl. Biophys J 84: 3743-3750.
29. Byrne B, Iwata S, (2002) Membrane protein complexes. Curr Opin Struct Biol 12: 239-243.
30. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD, (2003) Improved protein-ligand docking using GOLD. Proteins 52: 609-623.
31. Paterlini MG, (2002) Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys J 83: 3012-3031.
32. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, et al.(2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
33. Bayry J, Flower DR, Tough DF, Kaveri SV, (2008) From 'perfect mix' to 'potion magique'-regulatory T cells and anti-inflammatory cytokines as adjuvant targets. Nat Rev Microbiol 6: C1.
34. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, et al.(2008) In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A 105: 10221-10226.
35. Chaitra MG, Shaila MS, Nayak R, (2008) Characterization of T-cell immunogenicity of two PE/PPE proteins of Mycobacterium tuberculosis. J Med Microbiol 57: 1079-1086.
36. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, et al.(1996) Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173: 765-769.
37. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, et al.(2008) Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14: 819-821.
38. Kornbluth RS, Stone GW, (2006) Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J Leukoc Biol 80: 1084-1102.
39. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al.(2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
40. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, et al.(1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96: 5698-5703.
41. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, et al.(2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 97: 5639-5644.
42. Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT, (2003) CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med 198: 889-901.
43. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, et al.(2007) Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol 178: 2961-2972.
44. Easterbrook JD, Zink MC, Klein SL, (2007) Regulatory T cells enhance persistence of the zoonotic pathogen Seoul virus in its reservoir host. Proc Natl Acad Sci U S A 104: 15502-15507.
45. Taguchi O, Takahashi T, (1996) Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease. Eur J Immunol 26: 1608-1612.
46. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, et al.(2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823-832.
47. Seder RA, Hill AV, (2000) Vaccines against intracellular infections requiring cellular immunity. Nature 406: 793-798.
48. Reed SG, Bertholet S, Coler RN, Friede M, (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
49. Ishii KJ, Akira S, (2007) Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 27: 363-371.
50. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
51. Hattotuwagama CK, Davies MN, Flower DR, (2006) Receptor-ligand binding sites and virtual screening. Curr Med Chem 13: 1283-1304.
52. Gaulton A, Attwood TK, (2003) Bioinformatics approaches for the classification of G-protein-coupled receptors. Curr Opin Pharmacol 3: 114-120.
53. Vriend G, (1990) WHAT IF: a molecular modeling and drug design program. J Mol Graph 8: 52-56.
54. Price DJ, Brooks CL 3rd, (2004) A modified TIP3P water potential for simulation with Ewald summation. J Chem Phys 121: 10096-10103.
55. Blanpain C, Lee B, Vakili J, Doranz BJ, Govaerts C, et al.(1999) Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 274: 18902-18908.
56. Homer RW, Swanson J, Jilek RJ, Hurst T, Clark RD, (2008) SYBYL Line Notation (SLN): A Single Notation To Represent Chemical Structures, Queries, Reactions, and Virtual Libraries. J Chem Inf Model 48: 2294-22307.
57. Flower DR, (1998) DISSIM: a program for the analysis of chemical diversity. J Mol Graph Model 16: 239-253.
58. Sadowski J, (1997) A hybrid approach for addressing ring flexibility in 3D database searching. J Comput Aided Mol Des 11: 53-60.
59. Cabaniols JP, Cibotti R, Kourilsky P, Kosmatopoulos K, Kanellopoulos JM, (1994) Dose-dependent T cell tolerance to an immunodominant self peptide. Eur J Immunol 24: 1743-1749.
60. Hutchings CL, Gilbert SC, Hill AV, Moore AC, (2005) Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175: 599-606.